New drug - Celsentri for HIV

Pfizer has launched Celsentri (maraviroc), indicated in combination with other antiretrovirals, for treatment-experienced adults infected with only CCR5-tropic HIV-1.

PHARMACOLOGY
Maraviroc is the first in a new class of antiretrovirals called CCR5 antagonists. Maraviroc blocks the interaction between HIV-1 and the CCR5 chemokine co-receptor on the CD4 T-cell membrane, preventing the virus from entering T-cells.

It is effective only against those strains of HIV-1 that are CCR5-tropic (i.e. use the CCR5 co-receptor to gain entry to cells). Maraviroc is not active against viruses which use CXCR4 as their entry co-receptor. Therefore, tropism testing should be done prior to starting treatment to ensure that CXCR4 or dual/mixed-tropic viruses are not detected.

 

CLINICAL STUDIES
The efficacy of maraviroc has been evaluated in two ongoing trials (MOTIVATE 1 and 2, n=1076). At study entry, patients with CCR5-tropic HIV-1 infection had a viral load of >5,000 copies/ml with prior exposure to at least one agent from three classes of antiretrovirals, or resistance or intolerance to at least one member of each drug class.


Patients were placed on an optimised background therapy (OBT) regimen with three to six antiretrovirals, and then randomised to receive maraviroc 300mg once daily, maraviroc 300mg twice daily or placebo. The dose of maraviroc was adjusted depending on co-administered medication and the results for the licensed twice-daily regimen are given below.


Pooled analysis1 after 48 weeks showed that maraviroc plus OBT was superior to placebo plus OBT in achieving undetectable viral load (<50 copies/ml); 45.5 per cent in the maraviroc arm, compared with 16.7 per cent for placebo. Mean change from baseline in CD4 cell count was 124.07 cells/mm3 in the maraviroc arm, compared to 60.93 cells/mm3 for placebo. There were no clinically relevant differences in the safety profile between the treatment groups.

1. Celsentri Summary of Product Characteristics, 17th September 2007; Pfizer.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)